This article was originally published in The Gray Sheet
Comments are due within 30 days of the March 1 publication in the Federal Register of the Medical Devices Draft Guidance for Clinical Laboratory Improvement Amendments of 1988 Criteria for Waiver. The guidance includes an alternate path to waiver based on user comparability criteria, but also retains methods laid out in the 1995 proposed rule (1"The Gray Sheet" Jan. 29, 2001, p. 3)
You may also be interested in...
Manufacturers seeking waived status for diagnostic tests under user-based criteria will need to perform agreement studies with at least 300 untrained users to show that those users obtain the same results as lab professionals, according to an FDA draft guidance issued Jan. 23.
Towa’s US-based Breckenridge is aiming for exclusivity with its generic version of Amgen’s Kyprolis – developed with partner Natco Pharma – after obtaining one of the first approvals for several strengths of the treatment for relapsed or refractory multiple myeloma.
As Nestlé continues to expand its presence in the VMS market it will not take a brand popular in one country and “force” that name on consumers in a different part of the world, says CEO Mark Schneider.